BioSpace News Archive

Global biopharmaceutical services leader, Allucent, announced today the appointment of Katy Moore, PharmD, RPh, as president of Clinical Pharmacology, Modeling and Simulation (CPMS).

Codagenix Inc. today announced that it has completed dosing of its Phase 1 clinical trial to evaluate CodaVax™-H1N1, a universal, live-attenuated influenza vaccine.

Study shows that DecisionDx®-Melanoma results can provide patients with knowledge and understanding regarding their prognosis and inform melanoma treatment decisions.

Cardiawave Confirms the Safety of VALVOSOFT ® its Non-Invasive Ultrasound Treatment for Aortic Stenosis.

Proscia® , a leader in digital and computational pathology solutions, has raised $37 million to advance the way we understand and treat diseases like cancer.

Type B meeting scheduled with FDA Division of Cardiology and Nephrology.

Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”) , are pleased to announce that Dr. John Kellum, the Company’s CMO, will be featured as the keynote lecturer at the virtual 40th Vicenza Course.

Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports.

Avid Bioservices, Inc. today announced the opening of the analytical and process development (AD/PD) suites within the company’s new, world-class viral vector development and CGMP manufacturing facility.